Clinical Trial

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

Name: Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA — clinical trial record (NCT06868290)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

Protocol Amendment History 1 change

notable Trial sites expanded: 31 -> 35 locations 2026-05-21

Trial Details

NCT Number	NCT06868290
Lead Sponsor	Novartis Pharmaceuticals
Conditions	ANCA Associated Vasculitis (AAV)
Enrollment	126 participants
Start Date	2025-03-13
Primary Completion	2029-06-07 (estimated)
Study Completion	2030-05-24 (estimated)
Updated on ClinicalTrials.gov	2026-05-20